Abstract:Aging leads to several geriatric conditions including osteoporosis (OP) and associated frailty syndrome. Treatments for these conditions are limited and none target fundamental drivers of pathology, and thus identifying strategies to delay progressive loss of tissue homeostasis and functional reserve will significantly improve quality of life in elderly individuals. A fundamental property of aging is the accumulation of senescent cells. Senescence is a cell state defined by loss of proliferative capacity, resistance to apoptosis, and the release of a proinflammatory and anti-regenerative senescence-associated secretory phenotype (SASP). The accumulation of senescent cells and SASP factors is thought to significantly contribute to systemic aging. Senolytics—compounds which selectively target and kill senescent cells—have been characterized to target and inhibit anti-apoptotic pathways that are upregulated during senescence, which can elicit apoptosis in senescent cells and relieve SASP production. Senescent cells have been linked to several age-related pathologies including bone density loss and osteoarthritis in mice. Previous studies in murine models of OP have demonstrated that targeting senescent cells pharmacologically with senolytic drugs can reduce symptomology of the disease. Here, we demonstrate the efficacy of senolytic drugs (dasatinib, quercetin, and fisetin) to improve age-associated degeneration in bone using the Zmpste24−/− (Z24−/−) progeria murine system for Hutchinson–Gilford progeria syndrome (HGPS). We found that the combination of dasatinib plus quercetin could not significantly mitigate trabecular bone loss although fisetin administration could reduce bone density loss in the accelerated aging Z24−/− model. Furthermore, the overt bone density loss observed in the Z24−/− model reported herein highlights the Z24 model as a translational model to recapitulate alterations in bone density associated with advanced age. Consistent with the “geroscience hypothesis,” these data demonstrate the utility of targeting a fundamental driver of systemic aging (senescent cell accumulation) to alleviate a common condition with age, bone deterioration.

Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function

Progerin modulates the IGF-1R/Akt signaling involved in aging

In vivo cyclic induction of the FOXM1 transcription factor delays natural and progeroid aging phenotypes and extends healthspan

The Senolytic Drug Fisetin Attenuates Bone Degeneration in the Zmpste24−/− Progeria Mouse Model

Resveratrol Rescues Sirt1-Dependent Adult Stem Cell Decline and Alleviates Progeroid Features in Laminopathy-Based Progeria

Telomeric epigenetic response mediated by Gadd45a regulates stem cell aging and lifespan.

Targeting CK2 eliminates senescent cells and prolongs lifespan in Zmpste24 -deficient mice

Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production

Growth hormone receptor gene disruption in mature‐adult mice improves male insulin sensitivity and extends female lifespan

Insulin sensitivity in long-lived growth hormone-releasing hormone knockout mice

Influence of Cardiac-Specific Overexpression of Insulin-Like Growth Factor 1 on Lifespan and Aging-Associated Changes in Cardiac Intracellular Ca2+ Homeostasis, Protein Damage and Apoptotic Protein Expression.

Reduced Circulating Insulin Enhances Insulin Sensitivity in Old Mice and Extends Lifespan

GDF11 administration does not extend lifespan in a mouse model of premature aging

Targeted partial reprogramming of age-associated cell states improves markers of health in mouse models of aging

Doxycycline decelerates aging in progeria mice

IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice

Genetic Disruption of KLF1 K74 SUMOylation in Hematopoietic System Promotes Healthy Longevity in Mice

Unique progerin C-terminal peptide ameliorates Hutchinson–Gilford progeria syndrome phenotype by rescuing BUBR1

Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice

Inhibition of poly(ADP-Ribosyl)ation reduced vascular smooth muscle cells loss and improves aortic disease in a mouse model of human accelerated aging syndrome

Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice